UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Metabolism, clinical and experimental, 2018-08, Vol.85, p.32-37

2018

Volltextzugriff (PDF)

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

The Lancet (British edition), 2013-09, Vol.382 (9896), p.941-950

2013

Volltextzugriff (PDF)

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Circulation (New York, N.Y.), 2019-05, Vol.139 (22), p.2528-2536

2019

Volltextzugriff (PDF)

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

The American heart journal, 2018-06, Vol.200, p.83-89

2018

Volltextzugriff (PDF)

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study

Diabetes care, 2020-02, Vol.43 (2), p.468-475

2020

Volltextzugriff (PDF)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Cardiovascular diabetology, 2019-06, Vol.18 (1), p.73-73, Article 73

2019

Volltextzugriff (PDF)

Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials

The lancet. Diabetes & endocrinology, 2013-12, Vol.1 (4), p.317-328

2013

Volltextzugriff (PDF)

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Cardiovascular diabetology, 2019-11, Vol.18 (1), p.149-10, Article 149

2019

Volltextzugriff (PDF)

Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus

Journal of diabetes and its complications, 2015-04, Vol.29 (3), p.438-444

2015

Volltextzugriff (PDF)

Gaps and barriers in the control of blood glucose in people with type 2 diabetes

Diabetes & vascular disease research, 2017-05, Vol.14 (3), p.172-183

2017

Volltextzugriff (PDF)

Ticagrelor in Patients with Stable Coronary Disease and Diabetes

The New England journal of medicine, 2019-10, Vol.381 (14), p.1309-1320

2019

Volltextzugriff (PDF)

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

Atherosclerosis, 2018-10, Vol.277, p.195-203

2018

Volltextzugriff (PDF)

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum

Diabetes care, 2018-01, Vol.41 (1), p.14-31

2018

Volltextzugriff (PDF)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

European journal of preventive cardiology, 2020-04, Vol.27 (6), p.593-603

2020

Volltextzugriff (PDF)

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

Cardiovascular diabetology, 2017-05, Vol.16 (1), p.70-70, Article 70

2017

Volltextzugriff (PDF)

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease

The American journal of cardiology, 2008-12, Vol.102 (11), p.1495-1501

2008

Volltextzugriff (PDF)

Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia

The American journal of clinical nutrition, 2006-03, Vol.83 (3), p.582-591

2006

Volltextzugriff (PDF)

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

Journal of the American Heart Association, 2017-08, Vol.6 (8), p.n/a

2017

Volltextzugriff (PDF)

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

The lancet. Diabetes & endocrinology, 2017-12, Vol.5 (12), p.941-950

2017

Volltextzugriff (PDF)

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

The lancet. Diabetes & endocrinology, 2013-10, Vol.1 (2), p.123-131

2013

Volltextzugriff (PDF)

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1

Circulation (New York, N.Y.), 2018-09, Vol.138 (13), p.1304-1316

2018

Volltextzugriff (PDF)

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease

The American journal of cardiology, 2008-12, Vol.102 (11), p.1489-1494

2008

Volltextzugriff (PDF)

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

Diabetes care, 2015-07, Vol.38 (7), p.1218-1227

2015

Volltextzugriff (PDF)

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Circulation (New York, N.Y.), 2019-11, Vol.140 (19), p.1569-1577

2019

Volltextzugriff (PDF)

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2210-2219

2018

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Aktive Filter

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(89)

Publikationsform

Artikel
(101)

Sprache

Englisch
(101)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Humans
(101)
Life Sciences & Biomedicine
(93)
Science & Technology
(93)
Female
(75)
Male
(75)
Middle Aged
(73)
Aged
(61)
Cardiovascular System & Cardiology
(54)
Diabetes Mellitus, Type 2 - Drug Therapy
(52)
Cardiac & Cardiovascular Systems
(47)
Risk Factors
(37)
Diabetes
(34)
Double-Blind Method
(33)
Endocrinology & Metabolism
(33)
Time Factors
(27)
Adult
(25)
Cardiovascular Disease
(25)
Diabetes Mellitus
(25)
Diabetes Mellitus, Type 2 - Complications
(25)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus

Gaps and barriers in the control of blood glucose in people with type 2 diabetes

Ticagrelor in Patients with Stable Coronary Disease and Diabetes

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease

Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Aktive Filter

Suchergebnisse filtern